Literature DB >> 11423262

Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals.

E Vaccher1, M Spina, U Tirelli.   

Abstract

As the AIDS epidemic advances, the spectrum of malignancies encountered is expanding. Several non-AIDS defining cancers, i.e. Hodgkin's disease (HD), anal and testicular cancer, are increasing in incidence in HIV-infected patients. The widespread use of highly active antiretroviral therapy (HAART) in industrialised countries has resulted in substantial improvement in the survival of HIV-infected patients. It is likely that in the future, cancers associated with long-term mild immune suppression will occur at an increased rate in long-term survivors of HIV infection. The natural history of the majority of non-AIDS defining tumours differs from that of the general population. Unusual aspects of tumour localisation, growth behaviour and therapeutical responses distinguish tumours in patients with HIV infection from those without. This paper reviews the most relevant data on the epidemiology, pathology, clinical features and treatment of the most frequently reported non-AIDS defining tumours, i.e. HD, lung, testicular and skin cancers.

Entities:  

Mesh:

Year:  2001        PMID: 11423262     DOI: 10.1016/s0959-8049(01)00122-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Fever in the recently returned HIV infected traveller.

Authors:  A Birnie; B G Gazzard; C Bacon; A Dogan; P J Shaw; R F Miller
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

Review 2.  Diagnosis and management of lymphomas and other cancers in HIV-infected patients.

Authors:  Antonino Carbone; Emanuela Vaccher; Annunziata Gloghini; Liron Pantanowitz; Akin Abayomi; Paolo de Paoli; Silvia Franceschi
Journal:  Nat Rev Clin Oncol       Date:  2014-03-11       Impact factor: 66.675

Review 3.  Hodgkin lymphoma in patients with HIV infection: a review.

Authors:  Nihal Martis; Nicolas Mounier
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 4.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

5.  Disparities in survival after Hodgkin lymphoma: a population-based study.

Authors:  Theresa H M Keegan; Christina A Clarke; Ellen T Chang; Sarah J Shema; Sally L Glaser
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

6.  Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study.

Authors:  Daria Gotti; Elena Raffetti; Laura Albini; Laura Sighinolfi; Franco Maggiolo; Elisa Di Filippo; Nicoletta Ladisa; Gioacchino Angarano; Giuseppe Lapadula; Angelo Pan; Anna Degli Esposti; Massimiliano Fabbiani; Emanuele Focà; Alfredo Scalzini; Francesco Donato; Eugenia Quiros-Roldan
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

7.  Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma.

Authors:  Ikram Ul-Haq; Alessia Dalla Pria; Elisa Suardi; David J Pinato; Fieke Froeling; John Forni; Paul Randell; Mark Bower
Journal:  Med Oncol       Date:  2018-03-13       Impact factor: 3.064

8.  Breast self-examination and its associated factors among women who attended anti-retroviral therapy clinic in Bahir Dar city administration, North West Ethiopia.

Authors:  Betelhem Wondie; Amanu Aragaw; Gizachew Worku; Nigus Kassie
Journal:  SAGE Open Med       Date:  2022-09-20

9.  Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study.

Authors:  Theresa H M Keegan; Mindy C DeRouen; Helen M Parsons; Christina A Clarke; Debbie Goldberg; Christopher R Flowers; Sally L Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01-29       Impact factor: 4.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.